Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | S100A4 | P26447 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29600703 | 1.00 | ERN1 (0.41) | ERN1KMT2AHTTMEN1POLB | |
| SCHEMBL6512051 | 0.83 | ERN1 (0.41) | ERN1KMT2AHTTMEN1POLB | |
| SCHEMBL2082959 | 0.82 | ALDH1A1 (0.50) | KMT2AHTTMEN1ALDH1A1CYP1A2 | |
| SCHEMBL27732124 | 0.82 | KMT2A (0.41) | ERN1KMT2AHTTMEN1POLB | |
| SCHEMBL126405 | 0.80 | SMN1; SMN2 (0.54) | ALDH1A1CYP1A2CYP3A4SMN1; SMN2MAPT | |
| SCHEMBL1721986 | 0.80 | ALDH1A1 (0.35) | ERN1KMT2AHTTMEN1POLB | |
| SCHEMBL422756 | 0.80 | ERN1 (0.39) | ERN1KMT2AMEN1POLBPKM | |
| SCHEMBL4048642 | 0.80 | ERN1 (0.39) | ERN1KMT2AHTTMEN1POLB | |
| SCHEMBL7010585 | 0.80 | HSP90AA1 (0.42) | ERN1KMT2AMEN1ALDH1A1CYP1A2 | |
| SCHEMBL742711 | 0.80 | CYP1A2 (0.43) | ERN1KMT2AMEN1POLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 286 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112441970-A | 2, 5-disubstituted-3-aminopyridine compound and preparation method and application thereof | 天津医科大学 | 2021-03-05 | — | — | CN | claimed |
| US-12610730-B2 | Metal complex and light emitting device | CITY UNIVERSITY OF HONG KONG (HK) | 2026-04-21 | — | — | US | disclosed |
| US-20260103464-A1 | CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYLSULPHONYL-PYRIDINE DERIVATIVES | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2026-04-16 | — | — | US | disclosed |
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | TERREMOTO BIOSCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12514251-B2 | Fused heterocyclic compounds and their use as pest control agents | PI INDUSTRIES LTD. (IN) | 2026-01-06 | — | — | US | disclosed |
| WO-2025081045-A9 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-12435083-B2 | Cyclopropyl-(hetero)aryl-substituted ethylsulphonyl-pyridine derivatives | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-10-07 | — | — | US | disclosed |
| US-20250289819-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-09-18 | — | — | US | disclosed |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| WO-2025096751-A1 | MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE | ESPERION THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2004054582-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | NEUROGEN CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| US-20040106616-A1 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION | 2004-06-03 | — | — | US | disclosed |
| WO-2003062209-A2 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN | NEUROGEN CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
| EP-0573878-B1 | 3-fluoropyridines, process for their preparation and their use in liquid crystal mixtures | AVENTIS RES & TECH GMBH & CO (DE) | 2000-12-20 | — | — | EP | disclosed |
| US-5445763-A | Ferroelectricity; switching and/or display devices containing outer plates, electrodes, at least one polarizer and one alignment layer | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-08-29 | — | — | US | disclosed |
| EP-0649409-A1 | VINYL ARENAS HAVING RETINOID-LIKE ACTIVITY | ALLERGAN, INC. (US) | 1995-04-26 | — | — | EP | disclosed |
| WO-1993025529-A1 | 3-FLUOROPYRIDINES, METHOD OF PREPARING THEM AND THEIR USE IN LIQUID-CRYSTAL MIXTURES | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-12-23 | — | — | WO | disclosed |
| WO-1993025530-A2 | VINYL ARENAS HAVING RETINOID-LIKE ACTIVITY | ALLERGAN, INC. (US) | 1993-12-23 | — | — | WO | disclosed |
| EP-0573878-A1 | 3-fluoropyridines, process for their preparation and their use in liquid crystal mixtures | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-12-15 | — | — | EP | disclosed |
| EP-0013145-A2 | Substituted anilinopyridines, processes for their preparation and intermediates for use therein, compositions and herbicidal use thereof | ICI AUSTRALIA LIMITED (AU) | 1980-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12610730-B2 | Metal complex and light emitting device | OPRD1, OCIAD2, ORC3 | ERN1 3422/4885KMT2A 4343/4885HTT 3146/4885 |
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | AKT1, AKT2, AKT3 | ERN1 517/4885KMT2A 1229/4885HTT 3562/4885 |
| US-20250289819-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | AKT1, AKT2, AKT3 | ERN1 1257/4885KMT2A 932/4885HTT 2987/4885 |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | ERN1 219/4885KMT2A 1011/4885HTT 4286/4885 |
| US-12435083-B2 | Cyclopropyl-(hetero)aryl-substituted ethylsulphonyl-pyridine derivatives | CYCS, CYP2E1, CYP1A1 | ERN1 3336/4885KMT2A 3576/4885HTT 1176/4885 |
| US-20260103464-A1 | CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYLSULPHONYL-PYRIDINE DERIVATIVES | CBR3, CYCS, CBR1 | ERN1 2053/4885KMT2A 3293/4885HTT 3365/4885 |
| US-20040106616-A1 | Substituted quinazolin-4-ylamine analogues | PIGS, HRH4, GPR88 | ERN1 4434/4885KMT2A 2473/4885HTT 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.